Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 Salvage and Haplo-Cord Transplant in R/R AML/MDS
NCT03393611Phase 1Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Nov 2012
- Primary completion
- Aug 2021
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daunorubicin + cytarabine liposome in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Weill Cornell Medicine. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 1 year, Neutrophil Engraftment at 100 days and 2 more. Started Nov 2012; status: completed.
02
Drugs
daunorubicin + cytarabine liposome
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03393611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03393611.